Nappi Carmine, Di Spiezio Sardo Attilio, Greco Elena, Tommaselli Giovanni A, Giordano Elena, Guida Maurizio
Department of Gynecology and Obstetrics, and Pathophysiology of Human Reproduction, University of Naples Federico II, Naples, Italy.
Obstet Gynecol. 2005 Jan;105(1):53-60. doi: 10.1097/01.AOG.0000148344.26475.fc.
To compare the effects of a new 21-day combined oral contraceptive containing 30 microg ethinyl/estradiol plus 3 mg drospirenone with a 21-day preparation containing 30 microg ethinyl/estradiol plus 75 microg gestodene on bone turnover and bone mineral density in young fertile women.
A randomized, controlled trial was conducted with healthy fertile women treated with 30 microg ethinyl/estradiol plus 3 mg drospirenone (group A; n = 24), 30 microg ethinyl/estradiol plus 75 microg gestodene (group B; n = 24) and healthy controls (group C, n = 23). At 3, 6, 9, and 12 months of the study, serum and urinary calcium, osteocalcin, urinary pyridinoline, and deoxypyridinoline were measured. At baseline and after 12 months, lumbar bone mineral density was determined by dual-energy X-ray absorptiometry.
In groups A and B, urinary pyridinoline and deoxypyridinoline at 6, 9, and 12 months were significantly reduced in comparison with basal values and group C (P < .05). Pyridinoline and deoxypyridinoline levels were lower in group A than in group B throughout the study, but not significantly. In group A serum calcium levels were significantly increased after 6 months. At 12 months, no significant difference was detected in lumbar bone mineral density values among the 3 groups and in comparison with basal values.
Both combined oral contraceptives exert a similar positive influence on bone turnover and bone-sparing effect in young postadolescent women.
比较一种含30微克炔雌醇/雌二醇加3毫克屈螺酮的新型21天复方口服避孕药与一种含30微克炔雌醇/雌二醇加75微克孕二烯酮的21天制剂对年轻育龄妇女骨转换和骨密度的影响。
对健康育龄妇女进行一项随机对照试验，其中一组接受30微克炔雌醇/雌二醇加3毫克屈螺酮治疗（A组；n = 24），一组接受30微克炔雌醇/雌二醇加75微克孕二烯酮治疗（B组；n = 24），还有一组为健康对照组（C组，n = 23）。在研究的第3、6、9和12个月，测量血清和尿钙、骨钙素、尿吡啶啉和脱氧吡啶啉。在基线和12个月后，通过双能X线吸收法测定腰椎骨密度。
与基础值及C组相比，A组和B组在第6、9和12个月时尿吡啶啉和脱氧吡啶啉显著降低（P <.05）。在整个研究过程中，A组的吡啶啉和脱氧吡啶啉水平低于B组，但差异不显著。A组血清钙水平在6个月后显著升高。在12个月时，三组之间的腰椎骨密度值与基础值相比无显著差异。
两种复方口服避孕药对年轻青春期后妇女的骨转换和骨质保护作用具有相似的积极影响。
